Table 1.
Characteristics of hospitalized and nonhospitalized patientsa
| Characteristics | Hospitalized n (%) | Nonhospitalized n (%) |
|---|---|---|
| Total cases (≥2 yr of age) | 597 (21.5) | 2182 (78.5) |
| Age (yr) | ||
| 2 to 5 | 154 (24.9) | 465 (75.1) |
| 6 to 12 | 237 (20.3) | 929 (79.7) |
| >12 | 206 (20.7) | 788 (79.3) |
| Gender | ||
| male | 353 (20.2) | 1391 (79.8) |
| female | 224 (21.6) | 791 (76.4) |
| Race | ||
| Caucasian | 356 (20.2) | 1409 (79.8) |
| African-American | 123 (25.1) | 367 (74.9) |
| Hispanic | 87 (23.0) | 291 (77.0) |
| other | 31 (22.0) | 110 (78.0) |
| Primary diagnosis | ||
| obstructive uropathy | 148 (23.0) | 496 (77.0) |
| FSGS | 50 (20.6) | 193 (79.4) |
| renal dysplasia | 60 (14.7) | 349 (85.3) |
| reflux nephropathy | 66 (23.5) | 215 (76.5) |
| other | 256 (22.3) | 894 (77.7) |
| Anemia (KDOQI) | ||
| HCT ≥ 33% | 328 (18.2) | 1474 (81.8) |
| HCT < 33% | 269 (27.5) | 708 (72.5) |
| Anemia (NHANES III) | ||
| z-score above −2 | 292 (18.8) | 1262 (81.2) |
| z-score below −2 | 305 (24.9) | 920 (75.1) |
| CKD stage | ||
| II | 105 (18.7) | 456 (81.3) |
| III | 316 (21.3) | 1171 (78.7) |
| IV | 148 (23.5) | 483 (76.5) |
| V | 28 (28.0) | 72 (72.0) |
| CRI registry year | ||
| before 1998 | 406 (22.2) | 1424 (77.8) |
| 1998 and after | 191 (20.1) | 758 (79.9) |
| Erythropoietin use | ||
| yes | 98 (29.8) | 231 (70.2) |
| no | 499 (20.4) | 1951 (79.6) |
| Growth hormone use | ||
| yes | 46 (20.9) | 174 (79.1) |
| no | 551 (21.5) | 2007 (78.5) |
| Calcium | ||
| low | 28 (22.6) | 96 (77.4) |
| normal | 386 (21.5) | 1413 (78.5) |
| high | 106 (23.8) | 340 (76.2) |
| Phosphorus | ||
| normal | 394 (21.0) | 1483 (79.0) |
| elevated | 160 (23.0) | 535 (77.0) |
| Parathyroid hormone | ||
| <2× upper limit | 200 (19.1) | 846 (80.1) |
| >2× upper limit | 130 (24.4) | 403 (75.6) |
| unknown | 267 (22.3) | 933 (77.7) |
| Iron supplementation | ||
| yes | 179 (28.2) | 456 (71.8) |
| no | 417 (19.5) | 1722 (80.5) |
| Antihypertensive medication use | ||
| yes | 258 (22.3) | 901 (77.8) |
| no | 339 (20.9) | 1280 (79.1) |
a
FSGS, focal segmental glomeruloscerosis; KDOQI, Kidney Disease Outcomes Quality Initiative; HCT, hematocrit; NHANES III, National Health and Nutrition Examination Survey III; CKD, chronic kidney disease; CRI, Chronic Renal Insufficiency registry.